This is a working overview of MC4 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
Reduction of Am(III) compounds with sodium amalgam yields Am(II) salts – the black halides AmCl2, AmBr2 and AmI2. They are very sensitive to oxygen and oxidize in water, releasing hydrogen and converting back to the Am(III) state. Specific lattice constants are:
=== Lack of efficacy === A 2022 meta-analysis by Leichsenring and others found that the treatment effects of psychotherapies and psychiatric drugs (i.e. "pharmacotherapies") is "limited", in spite of "half a century of research, thousands of RCTs and millions of invested funds". A 2012 review of meta-analyses found that psychiatric medications are about as effective as those used in general medicine. However, a 2023 umbrella review found that studies of mental health outcomes most often use symptom remission as the outcome of interest (36.9%) and recovery the least often (2.5%); further, the systematic reviews were often found to be of critically low quality (67.5%), individual studies at high risk of bias (98.8%), and analysis studies at high risk bias (97.7%).
By the time of the 2023 election, Peña was considered a conservative politician who opposes the legalization of abortion and same-sex marriage. In May 2017, however, he had stated that he was in favor of same-sex marriage, while saying in regards of abortion that he was open for it to "be discussed in a sincere environment and without prejudice". He reversed position shortly afterwards following criticism from conservative sectors. During his 2023 campaign, he promised to create 500,000 jobs. He also ruled out raising taxes. On foreign policy, Peña pledged to maintain Paraguay's diplomatic relations with the Republic of China (Taiwan). In May 2023, Peña announced that he intended to move the Paraguayan embassy in Israel from Tel Aviv to Jerusalem after being sworn in as president; a move that was previously made by Horacio Cartes in 2018, but reversed by Mario Abdo Benítez later that year. Peña eventually attended the inauguration of said embassy in December 2024. Peña and his government expressed vocal support for Israel during the Gaza war and the Twelve-Day War, with Paraguay siding with Israel during South Africa's genocide case against Israel. As president, Paraguay restored diplomatic relations with Venezuela in November 2023; relations were strained since 2019. Relations between the two nations were broken again in February 2025, however, after Peña recognized Edmundo González as the winner of the 2024 Venezuelan presidential election. On the 2026 United States intervention in Venezuela, Peña stated that "it can only bring good news".
Sources: en.wikipedia.org
=== Breast changes === Spironolactone can cause breast pain and enlargement in women. This is "probably because of estrogenic effects on target tissue." At low doses, breast tenderness has been reported in only 5% of women, but at high doses, it has been reported in up to 40% of women. Breast enlargement and tenderness may occur in 26% of women at high doses. Some women regard spironolactone-induced breast enlargement as a positive effect. Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men. At low doses, the rate is only 5 to 10%, but at high doses, up to or exceeding 50% of men may develop gynecomastia. In the RALES, 9.1% of men taking 25 mg/day spironolactone developed gynecomastia, compared to 1.3% of controls. Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100 mg/day, in 5 of 8 (62.5%) at 200 mg/day, and in 6 of 9 (66.7%) at 400 mg/day, relative to none of 12 controls. The severity of gynecomastia with spironolactone varies considerably, but is usually mild. As with breast enlargement caused by spironolactone in women, gynecomastia due to spironolactone in men is often, although inconsistently, accompanied by breast tenderness. In the RALES, only 1.7% of men developed breast pain, relative to 0.1% of controls. The time to onset of spironolactone-induced gynecomastia has been found to be 27 ± 20 months at low doses and 9 ± 12 months at high doses.
==== Works ==== A.A.A (EP), by Nigerian band A.A.A AAA (Lee Hwi-min album), 2022 AAA (Hyukoh and Sunset Rollercoaster album), 2024 Access All Areas (EP), by The AAA Girls, 2017 Access All Areas (Flo album), 2024, including a song titled "AAA" "AAA", a song on City (Strapping Young Lad album), 1997 "Aaa", a song by They Might Be Giants on their 2015 album Glean Greek: "ΑΑΑ (ΑΑΑ) και χωρίσαμε", romanized: AAA (AAA) kai korisame, lit. 'AAA (AAA) and we broke up', a song on Kravgi by Anna Vissi, 2000
== Research == In supramolecular chemistry, cyclodextrins are precursors to mechanically interlocked molecular architectures, such as rotaxanes and catenanes. Illustrative, α-cyclodextrin form second-sphere coordination complex with tetrabromoaurate anion ([AuBr4]-). β-Cyclodextrin complexes with certain carotenoid food colorants have been shown to intensify color, increase water solubility and improve light stability. Complexes formed between β-cyclodextrin and adamantane derivatives have been used to make self-healing materials, such as hydrogels and low-friction surfaces. Using the host-guest interaction between β-Cyclodextrin and Perfluorohexane, acoustically active nanoparticles were created. These nanoparticles were combined with histotripsy, leading to the development of Nanoparticle-Mediated Histotripsy (NMH). NMH addresses limitations of traditional histotripsy, such as non-selectivity and the requirement for high pressure. This promising new method has potential applications in cell ablation for various purposes, including cancer treatment.
== Working == A basic TDLAS setup consists of a tunable diode laser light source, transmitting (i.e. beam shaping) optics, optically accessible absorbing medium, receiving optics and detector/s. The emission wavelength of the tunable diode laser, viz. VCSEL, DFB, etc., is tuned over the characteristic absorption lines of a species in the gas in the path of the laser beam. This causes a reduction of the measured signal intensity due to absorption, which can be detected by a photodiode, and then used to determine the gas concentration and other properties as described later. Different diode lasers are used based on the application and the range over which tuning is to be performed. Typical examples are InGaAsP/InP (tunable over 900 nm to 1.6 μm), InGaAsP/InAsP (tunable over 1.6 μm to 2.2 μm), etc. These lasers can be tuned by either adjusting their temperature or by changing injection current density into the gain medium. While temperature changes allow tuning over 100 cm−1, it is limited by slow tuning rates (a few hertz), due to the thermal inertia of the system. On the other hand, adjusting the injection current can provide tuning at rates as high as ~10 GHz, but it is restricted to a smaller range (about 1 to 2 cm−1) over which the tuning can be performed. The typical laser linewidth is of the order of 10−3 cm−1 or smaller. Additional tuning, and linewidth narrowing, methods include the use of extracavity dispersive optics.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.